Why the study?
This study evaluated the long-term safety and effectiveness of ultrasound renal denervation in routine clinical practice across 9 EU countries.
What is the 12-month real-world safety and blood pressure-lowering effectiveness of ultrasound renal denervation in patients with uncontrolled hypertension?
Cohort (n=276)
Yes
What is the 12-month real-world safety and blood pressure-lowering effectiveness of ultrasound renal denervation in patients with uncontrolled hypertension?
Answers are grounded in this paper and cite their sources.
In a real-world European registry of 276 patients with uncontrolled hypertension, ultrasound renal denervation provided durable 12-month reductions in office (-18.7/-6.9 mmHg) and home (-11.6/-5.5 mmHg) blood pressure with no 30-day major vascular or renal artery complications.
Background The Global Paradise System (GPS) Registry is an ongoing real-world, all-comers study across 9 EU countries evaluating the long-term safety and effectiveness of ultrasound renal denervation (uRDN; Paradise System) in clinical practice. Methods Prospectively enrolled patients with uncontrolled hypertension (baseline office systolic blood pressure [OSBP] ≥140 mmHg) treated with uRDN were followed to 12 months. Office blood pressure (OBP), home blood pressure (HBP), and antihypertensive medications (AHM) were collected. Adjusted least-squares mean changes were estimated using a mixed model for repeated measures adjusted for baseline BP. Results Among 276 treated patients, mean age was 56.8 years and 41.3% were women. Comorbidities included elevated cardiovascular risk (47.8%), prior hypertensive crises (25.6%), diabetes (25.4%), and CKD (15.2%). Mean device time was 26.3 min, with 1.8 catheters/case. Through 30 days, no renal artery stenosis or vascular complications requiring intervention were reported. Baseline OBP was 171.3 ± 22.2/98.8 ± 15.9 mmHg (n = 276) and HBP was 163.8 ± 20.0/99.4 ± 15.4 mmHg (n = 132). At 12 months, OBP decreased by 18.7/6.9 mmHg and HBP by 11.6/5.5 mmHg, while AHM burden remained stable (−0.15 ± 1.45 medications, P = 0.467); 50% of patients achieved a ≥15 mmHg OSBP reduction. Patients with a history of hypertensive crises experienced greater 12-month reductions, with OBP decreasing by −20.0/−7.18 mmHg (n = 29). Conclusions In this real-world analysis from the GPS Registry, uRDN demonstrated durable safety profile and blood pressure reductions through 12 months.
No takes yet. Share an insight, caveat, or question.
Akbar et al. (2026) conducted a cohort in Uncontrolled hypertension (n=276). Ultrasound renal denervation (uRDN) was evaluated on 12-month adjusted least-squares mean change in office systolic blood pressure (OSBP) (MD -18.7 mmHg).
Synapse has enriched 10 related papers. Consider them for comparative context: